XML 41 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Geographic and Product Information
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Geographic and Product Information
Geographic and Product Information
Operations by Geographic Area:    Revenues primarily consisted of sales of REVLIMID®, ABRAXANE®, POMALYST®/IMNOVID®, OTEZLA®, VIDAZA®, azacitidine for injection, THALOMID®, and ISTODAX®. Additional sources of revenue included a licensing agreement with Novartis, which entitles us to royalties on FOCALIN XR® and the entire RITALIN® family of drugs, the sale of services through our Cellular Therapeutics subsidiary and other miscellaneous licensing agreements.
Revenues
 
2015
 
2014
 
2013
United States
 
$
5,604.0

 
$
4,482.8

 
$
3,862.1

Europe
 
2,624.3

 
2,310.8

 
1,865.7

All other
 
1,027.7

 
876.8

 
766.1

Total revenues
 
$
9,256.0

 
$
7,670.4

 
$
6,493.9

Long-Lived Assets1
 
2015
 
2014
United States
 
$
585.5

 
$
406.1

Europe
 
215.2

 
222.2

All other
 
13.4

 
14.3

Total long lived assets
 
$
814.1

 
$
642.6


1 
Long-lived assets consist of net property, plant and equipment.

Revenues by Product: Total revenues from external customers by product for the years ended December 31, 2015, 2014 and 2013 were as follows:
 
 
2015
 
2014
 
2013
REVLIMID®
 
$
5,801.1

 
$
4,980.0

 
$
4,280.3

ABRAXANE®
 
967.5

 
848.2

 
648.9

POMALYST®/IMNOVID®
 
983.3

 
679.7

 
305.4

OTEZLA®
 
471.7

 
69.8

 
—

VIDAZA®
 
590.7

 
611.9

 
803.3

azacitidine for injection
 
83.9

 
78.2

 
23.3

THALOMID®
 
185.4

 
221.2

 
244.5

ISTODAX®
 
69.1

 
65.6

 
54.0

Other
 
8.4

 
9.2

 
2.6

Total net product sales
 
9,161.1

 
7,563.8

 
6,362.3

Other revenue
 
94.9

 
106.6

 
131.6

Total revenue
 
$
9,256.0

 
$
7,670.4

 
$
6,493.9



Major Customers: We sell our products primarily through wholesale distributors and specialty pharmacies in the United States, which account for a large portion of our total revenues. International sales are primarily made directly to hospitals, clinics and retail chains, many of which are government owned. During the three-year period of 2015, 2014 and 2013, customers that accounted for more than 10% of our total revenue in at least one of those years are summarized below. The percentage of amounts due from these customers compared to total net accounts receivable is also summarized below as of December 31, 2015 and 2014.
 
 
Percent of Total Revenue
 
Percent of Net Accounts Receivable
Customer
 
2015
 
2014
 
2013
 
2015
 
2014
Amerisource Bergen Corp.
 
8.1
%
 
9.0
%
 
10.7
%
 
8.2
%
 
9.7
%
CVS
 
10.7
%
 
9.8
%
 
9.3
%
 
8.2
%
 
7.6
%